IntroductionYoung adulthood is a period of prosperity and freshness characterized by developmental achievement, which can be inhibited by various diseases such as cancer. Typically considered a terminal disease, if diagnosed in young adulthood, cancer may trigger a tremendous psychosomatic shock. The nature of facing a recent cancer diagnosis affects the whole coping process. Addressing young adults' experiences at the confirmation point of cancer diagnosis will facilitate supporting them through the early recognition of probable problems in the future. Therefore, the present study aimed to analyse the lived experiences of young adults facing a recent cancer diagnosis.MethodsThis qualitative study adopted an interpretive phenomenology design. In this study, 12 patients (with an age range of 20–40) were selected using the purposive sampling method. Data collection was done through in‐depth, semistructured interviews. The data were analysed following the method proposed by Diekelmann et al.FindingsThree main themes and nine subthemes were extracted from the data: (1) spiritual detachment and then acceptance through spirituality in the form of denial and then forced acceptance, sense of guilt and spiritual help‐seeking, and anger towards God and then humbleness, (2) the shock of facing an extraordinary life shaped by disturbed role‐play and unusual lifestyle, (3) anticipatory anxiety concerning the sense of rejection, negative perspective towards future, inability to afford the costs and worries about the future of the family members.ConclusionThis was the first study providing significant insights into the experiences of young adults facing a recent cancer diagnosis. The diagnosis of cancer can shadow all aspects of young adults' lives. The findings of the present study empower healthcare professionals to provide newly diagnosed young adults with appropriate health services.Patient ContributionsTo identify and recruit the participants, we explained the objectives of the present study to the unit managers either by phone or in person. The participants were approached and interviewed by three authors. Participation was voluntary and the participants received no financial contribution for their time.

Predictors of disease course in IBD would be beneficial for early determination of patient risk and appropriate medical therapy. To evaluate their predictive performance, endoscopic appearance, fecal calprotectin (Cp) and serological high sensitivity C‐reactive protein (hsCRP), markers of inflammation, were assessed in a prospective IBD (Crohn's disease [CD] and ulcerative colitis [UC]) inception cohort (<12 mo of diagnosis). Patients were observed at baseline and subsequent clinical visits (3 or 6 mo), where detailed endoscopic, clinical disease activity, and biomarker measurements were assessed. Of the 24 patients enrolled in the study, 14 were diagnosed with CD and 10 with UC. At enrolment, the median hsCRP was 4.1 mg/L (normal 0–7.0), and Cp was 644 μg/g (<50 normal). After therapy, the median Cp was 194 and 149 ug/g in CD (n=7) and UC (n=6), respectively. When stratified by clinical disease activity, no meaningful correlation between hsCRP and Cp was apparent, in contrast to a positive correlation with endoscopic appearance. Although the sample size is small, preliminary data suggest that the use of clinical disease activity measures in newly diagnosed IBD may be inadequate for determining inflammatory burden and for risk stratification. (Support from the Royal University Hospital Saskatoon and NSERC)